Treatment with the investigational anti-tau monoclonal antibody semorinemab significantly slowed decline in a measure of cognition among people with mild-to-moderate…
Articles by Marisa Horak, MS
Federal lawmakers are asking the U.S. Food and Drug Administration (FDA) to provide additional data and documents related to the…
Every participant in the Phase 2/3 GAIN clinical trial, which is testing Cortexyme’s experimental medication COR388 (atuzaginstat) in people…
Treatment with Aduhelm (aducanumab) slows the clinical decline observed in in Alzheimer’s across a range of cognitive and functional…
In clinical trials of the Alzheimer’s treatment Aduhelm (aducanumab), participants who experienced a greater reduction in brain levels of…
A panel of experts has crafted guidance for clinical use of Aduhelm (aducanumab), the first targeted treatment for…
On June 7, Aduhelm (aducanumab) became the first new treatment for Alzheimer’s disease to be approved by…
The U.S. Food and Drug Administration (FDA) has pulled back the controversial and sweeping approval recently given to …
Aduhelm (aducanumab), approved for Alzheimer’s disease in the U.S., is most appropriate for people with mild cognitive impairment (MCI)…
The National Institute on Aging (NIA) has awarded a five-year grant worth up to $5 million to support a clinical…